Stonebridge Capital Advisors’s Dr. Reddy's Laboratories RDY Stock Holding History

Stonebridge Capital Advisors’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-600	Closed	-$8.02K	–	697
2023 Q3	$8.02K	Hold	600	–	–	﹤0.01%	635
2023 Q2	$7.57K	Hold	600	–	–	﹤0.01%	658
2023 Q1	$6.83K	Hold	600	–	–	﹤0.01%	668
2022 Q4	$6.21K	Hold	600	–	–	﹤0.01%	671
2022 Q3	$6K	Hold	600	–	–	﹤0.01%	661
2022 Q2	$7K	Hold	600	–	–	﹤0.01%	665
2022 Q1	$7K	Hold	600	–	–	﹤0.01%	728
2021 Q4	$8K	Hold	600	–	–	﹤0.01%	678
2021 Q3	$8K	Hold	600	–	–	﹤0.01%	657
2021 Q2	$9K	Hold	600	–	–	﹤0.01%	632
2021 Q1	$7K	Buy	+600	New	+$7.71K	﹤0.01%	688
2020 Q3	–	Sell	-2,000	Closed	-$21K	–	581
2020 Q2	$21K	Hold	2,000	–	–	﹤0.01%	397
2020 Q1	$16K	Hold	2,000	–	–	﹤0.01%	421
2019 Q4	$16K	Hold	2,000	–	–	﹤0.01%	485
2019 Q3	$15K	Hold	2,000	–	–	﹤0.01%	499
2019 Q2	$15K	Buy	+2,000	New	+$15.7K	﹤0.01%	513

Other funds holding RDY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

Stonebridge Capital Advisors's RDY Position: Q4 2023 in Review

Stonebridge Capital Advisors sold out of Dr. Reddy's Laboratories (RDY) in Q4 2023, closing a stake of 600 shares — an estimated $8.02K sold.

Stonebridge Capital Advisors first reported a position in RDY in Q2 2019 and held it in 16 quarters. The position peaked at $21K in Q2 2020. 224 funds tracked by Wall St. Rank hold RDY as of Q4 2023.

Stonebridge Capital Advisors reported no remaining Dr. Reddy's Laboratories position as of Q4 2023 after selling out during the quarter.
Stonebridge Capital Advisors sold 600 Dr. Reddy's Laboratories shares in Q4 2023, an estimated $8.02K.
Stonebridge Capital Advisors first reported a position in Dr. Reddy's Laboratories in Q2 2019 and held it in 16 quarters.
Stonebridge Capital Advisors's Dr. Reddy's Laboratories position peaked at $21K in Q2 2020.
224 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q4 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.